Skip to main content

Advertisement

SpringerLink
Log in

Selective estrogen receptor modulators

  • Osteoporosis Drug Formulary Prescription Medications
  • Published:
Clinical Reviews in Bone and Mineral Metabolism Aims and scope Submit manuscript

Abstract

Selective estrogen receptor modulators (SERMs) competitively bind to estrogen receptors to act as agonists or antagonists in certain tissues, distinguishing the various available SERMS. Although tamoxifen, toremifene, and additional new compounds are discussed briefly, raloxifene is the only SERM currently indicated for the prevention and treatment of postmenopausal osteoporosis in women. The effects of raloxifene on vertebral fractures, nonvertebral fractures, and bone mineral density (BMD) have been explored. In the Multiple Outcomes of Raloxifene Evaluation (MORE) trial, vertebral fractures were significantly reduced in the raloxifene treatment group (relative risk of 0.60, 95% confidence interval 0.50–0.70, p<0.01). Raloxifene did not significantly reduce nonvertebral fractures with either 60 or 120 mg/d in the MORE trial. BMD increased by 0.4 to 1.20% at the lumbar spine and the effects have been documented for at least 7 yr in the Continuing Outcomes Relevant to Evista trial. Fracture prevention is greater than expected based on BMD changes. Adverse effects that should be considered with raloxifene include hot flushes and an increased risk for venous thromboembolism. Raloxifene is a viable option for postmenopausal patients with osteoporosis, particularly in patients at increased risk of invasive breast cancer. Although not yet indicated by the US Food and Drug Administration for breast cancer prevention, clinical trail data is encouraging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rossouw JE, Anderson GL, Prentice RL, et al. 2002 Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA 288:321–333.

    Article  PubMed  CAS  Google Scholar 

  2. Morello KC, Wurz GT, DeGregorio MW. 2002 SERMs: current status and future trends. Crit Rev. Oncol Hematol 43:63–76.

    PubMed  Google Scholar 

  3. Grese TA, Sluka JP, Bryant HU, et al. 1997 Molecular determinants of tissue selectivity in estrogen receptor modulators. Proc Natl Acad Sci USA 94:14,105–14,110.

    Article  CAS  Google Scholar 

  4. Mitlak BH, Cohen FJ. 1999 Selective estrogen receptor modulators: a look a head. Drugs 57:653–663.

    Article  PubMed  CAS  Google Scholar 

  5. Khovidhunkit W, Shoback DM. 1999. Clinical effects of raloxifene hydrochloride in women. Ann Intern Med 150:431–439.

    Google Scholar 

  6. Hodgson SF, Watts NB, Bilezikian JP, et al.; AACE Osteoporosis Task Force. 2003 American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 9:544–564.

    PubMed  Google Scholar 

  7. Walsh BW, Kuller LH, Wild RA, et al. 1998 Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 279:1445–1451.

    Article  PubMed  CAS  Google Scholar 

  8. Cranney A, Tugwell P, Zytaruk N, et al; and the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev 23:524–528.

    Article  PubMed  CAS  Google Scholar 

  9. Maricic M, Gluck O. 2002 Review of raloxifene and its clinical applications in osteoporosis. Expert Opin Pharmacother 3:767–775.

    Article  PubMed  CAS  Google Scholar 

  10. Institute for Clinical Systems Improvement Health Care Guideline: Diagnosis and Treatment of Osteoporosis. Institute for Clinical Systems Improvement Website. Available at: www.icsi.org. Last accessed on, October 1, 2004.

  11. McClung M, Omizo M, Weiss S, Moffit et al. 2004 Comparison of lasofoxifene and raloxifene for the prevention of bone loss in postmeno pausal women. J Bone Miner Met 19 (Suppl 1):S96 (abstract).

    Google Scholar 

  12. McClung M, Portman D, Emkey R, et al. Comparison of the extraskeletal effects of lasofoxifene and raloxifene. J Bone Miner Met 2004 19(Suppl 1):S174 (abstract)

    Google Scholar 

  13. Johnston SR, Gumbrell LA, Evans TR, et al. 2004 A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen. Cancer Chemother Pharmacol 53: 341–348.

    Article  PubMed  CAS  Google Scholar 

  14. Nuttall ME, Bradbeer JN, Stroup GB, et al. 1998 Idoxifene: a novel selective estrogen receptor modulator prevents bone loss and lowers cholesterol levels in ovariectomized rats and decreases uterine weight in intact rats. Endocrinology 139: 5224–5234.

    Article  PubMed  CAS  Google Scholar 

  15. Rutanen EM, Heikkinen J, Halonen K, Komi J, Lammintausta R, Ylikorkala O. 2003 Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. Menopause 10:433–439.

    Article  PubMed  Google Scholar 

  16. Ke HZ, Foley GL, Simmons HA, Shen V, Thompson DD. 2004 Long-term treatment of lasofoxifene preserves bone mass and bone strength and does not adversely affect the uterus in ovariectomized rats. Endocrinology 145: 1996–2005.

    Article  PubMed  CAS  Google Scholar 

  17. Burke TW, Walker CL. 2003 Arzoxifene as therapy for endometrial cancer. Gynecol Oncol 90(2 Pt. 2):S40-S46.

    Article  PubMed  CAS  Google Scholar 

  18. Ma YL, Bryant HU, Zeng Q, et al. 2002 Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in overiectomized rats. J Bone Miner Res 17:2256–2264.

    Article  PubMed  CAS  Google Scholar 

  19. Ke HZ, Simmons HA, Pirie CM, Crawford DT, Thompson DD. 1995 Droloxifene, a new estrogen antagonist/agonist, prevents bone loss in ovariectomized rats. Endocrinology 136:2435–2441

    Article  PubMed  CAS  Google Scholar 

  20. Bellmunt J, Sole L. 1991 European early phase II dose-finding study of droloxifene in advanced breast cancer. Am J Clin Oncol 14 (Suppl 2): S36-S39.

    Article  PubMed  Google Scholar 

  21. Buzdar A, Hayes D, El-Khoudary A, et al. Droloxifene 301 Study Group. 2002 Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat 73:161–175.

    Article  PubMed  CAS  Google Scholar 

  22. Ettinger B, Black DM, Mitlak BH, et al. 1999 Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 282:637–645.

    Article  PubMed  CAS  Google Scholar 

  23. Kanis JA, Johnell O, Black DM, et al. 2003 Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the Multiple Outcomes of Raloxifene Evaluation trial. Bone 33:293–300.

    Article  PubMed  CAS  Google Scholar 

  24. Delmas PD, Ensrud KE, Adachi JD, et al, and the Multiple Outcomes of Raloxifene Evaluation Investigators. 2002 Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609–3617.

    Article  PubMed  CAS  Google Scholar 

  25. Harris ST, Siris ES, Stock JL, et al. 2004 Increases in bone mineral density are maintained after 7 years of raloxifene therapy: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Met 19(Suppl 1):S56 (abstract).

    Google Scholar 

  26. Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. 2000 Longterm effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 160:3444–3450.

    Article  PubMed  CAS  Google Scholar 

  27. Delmas PD, Genart HK, Crans GG, et al. 2003 Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 33:522–532.

    Article  PubMed  CAS  Google Scholar 

  28. Siris ES, Harris ST, Eastell R, et al. 2004 Effects of raloxifene on the risk of nonvertebral fractures after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study. J Bone Miner Met 19(Suppl 1): S96 (abstract).

    Google Scholar 

  29. Cranney A, Guyatt G, Griffith L, et al., and the Osteoporosis Methodology Group and The Osteoporosis Research Advisory Group. 2002 Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 23:570–578.

    Article  PubMed  CAS  Google Scholar 

  30. Boivin G, Lips P, Ott SM, et al. 2003 Contribution of raloxifene and calcium and vitamin D3 supplementation to the increrase of the degree of mineralization of bone in postmenopausal women. J Clin Endocrinol Metab 88:4199–4205.

    Article  PubMed  CAS  Google Scholar 

  31. Holli K, Valavaara R, Blanco G, et al. 2000 Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group. J Clin Oncol 18:3487–3494.

    PubMed  CAS  Google Scholar 

  32. Cummings SR, Palermo L, Browner W, et al. 2000 Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283:1318–1321.

    Article  PubMed  CAS  Google Scholar 

  33. Jones KL, Buzdar AU. 2000 A review of adjuvant hormonal therapy in breast cancer. Endocr Relat Cancer 11:391–406.

    Article  CAS  Google Scholar 

  34. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC. 2002 Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599–603.

    Article  PubMed  CAS  Google Scholar 

  35. Love RR, Mazess RB, Barden HS, et al. 1992 Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856.

    Article  PubMed  CAS  Google Scholar 

  36. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med 99:636–641.

    Article  PubMed  CAS  Google Scholar 

  37. Love RR, Barden HS, Mazess RB, Epstein S, Chappell RJ. 1994 Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 154:2585–2588.

    Article  PubMed  CAS  Google Scholar 

  38. Marttunen MB, Hietanen P, Tiitinen A, Ylikorkala O. 1998 Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients. J Clin Endocrinol Metab 83:1158–1162.

    Article  PubMed  CAS  Google Scholar 

  39. Johnell O, Scheele WH, Lu Y, Reginster JY, Need AG, Seeman E. 2002 Additive effects of raloxifene and alendronate on bone density and biochemical markers of bone remodeling in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 87:985–992.

    Article  PubMed  CAS  Google Scholar 

  40. Ettinger B, Bilezikian JP. 2002 For osteoporosis, are two antiresorptive drugs better than one? J Clin Endocrinol Metab 87:983–984.

    Article  PubMed  CAS  Google Scholar 

  41. Ettinger B, San Martin J, Crans G, Pavo I. 2004 Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. J Bone Miner Res 19:745–751.

    Article  PubMed  CAS  Google Scholar 

  42. Cosman F, Nieyes J, Barburn N, Zion M, Lindsay R. 2004 Parathyroid hormone added to raloxifene and subsequent maintenance of BMD gain with raloxifene alone. J Bone Miner Met 19(Suppl 1):S98 (abstract).

    Google Scholar 

  43. Osteoporosis Prevention, Diagnosis and Therapy. 2001 National Institutes of Health Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. JAMA 285:785–795.

    Article  Google Scholar 

  44. Management of postmenopausal osteoporosis: position statement of the North American Menopause Society, 2002 J Am Menopause 9:84–101.

  45. Kung AW, Chao HT, Huang KE, et al. 2003 Efficacy and safety of raloxifene 60 milligrams/day in postmenopausal Asian women. J Clin Endocrinol Metab 88:3130–3136.

    Article  PubMed  CAS  Google Scholar 

  46. Uebelhart B, Herrmann F, Pavo I, Draper MW, Rizzoli R, 2004 Raloxifene treatment is associated with increased serum estradiol and decreased bone remodeling in healthy middle-aged men with low sex hormone levels. J Bone Miner Res 19:1518–1524.

    Article  PubMed  CAS  Google Scholar 

  47. Osteoporosis Society of Canada. Available at: http:// www.osteoporosis.ca. Last accessed on: October 3, 2004.

  48. Roth M. Osteoporosis guidelines. Clin Rev Bone Miner Metab 2004 2: 315–324.

    Article  Google Scholar 

  49. Duschek EJ, Gooren LJ, Netelenbos C. 2004 Effects of raloxifene on gonadotropins, sex hormones, bone turnover and lipids in healthy elderly men. Eur J Endocrinol 50:539–546.

    Article  Google Scholar 

  50. Walsh BW, Paul S, Wild RA, Dean et al. 2000 The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab 85:214–218.

    Article  PubMed  CAS  Google Scholar 

  51. Barrett-Connor E, Ensrud KE, Harper K, Mason et al. 2003 Post hoc analysis of data from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial on the effects of three years of raloxifene treatment on glycemic control and cardiovascular disease risk factors in women with and without type 2 diabetes. Clin Ther 25:919–930.

    Article  PubMed  CAS  Google Scholar 

  52. O'Riondan M. 2004 Use of raloxifene to prevent CHD: more data needed from the upcoming RUTH trial. Accessed at http://www.theheart.org/view Article.do?primaryKey=56506 1 on September 1, 2004.

  53. Mosca L, Barrett-Connor E, Wenger NK, et al. 2001 Design and methods of the Raloxifene Use for The Heart (RUTH) study. Am J Cardiol 88:392–395.

    Article  PubMed  CAS  Google Scholar 

  54. Cummings SR, Eckert S, Krueger KA, et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189–2197.

    Article  PubMed  CAS  Google Scholar 

  55. Cauley JA, Norton L, Lippman ME, et al. 2001 Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134.

    Article  PubMed  CAS  Google Scholar 

  56. Barrett-Connor E, Powles TJ, Mershon JL, et al. 2004 Incidence of invasive breast cancer following 8 years of raloxifene therapy in postmenopausal women with osteoporosis: results from the Continuing Outcomes Relevent to Evista (CORE) trial. J Clin Onc 22(Suppl 14):1000 (abstract).

    Google Scholar 

  57. Schwartz J. 2004 Tamoxifen: an emerging preventive. Front Biosci 9:2827–2847.

    Article  PubMed  CAS  Google Scholar 

  58. No authors. 2000 STAR: first-year recruitment efforts set brisk pace for future. CA Cancer J Clin. 50:271–272.

  59. Barrett-Connor E, Cauley JA, Kulkarni PM, Sashegyi A, Cox DA, Geiger MJ. 2004 Risk-benefit profile for raloxifene: 4-year data from the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial. J Bone Miner Res 19:1270–1275.

    Article  PubMed  CAS  Google Scholar 

  60. Cohen I, Rosen DJ, Shapira J, et al. 1994 Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic, postmenopausal breast cancer patients. Gynecol Oncol 52:185–190.

    Article  PubMed  CAS  Google Scholar 

  61. Davies GC, Huster WJ, Lu Y, Plouffe L Jr, Lakshmanan M. 1999 Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 93:558–565.

    Article  PubMed  CAS  Google Scholar 

  62. Eli Lilly and Company. 2003 Evista (raloxifene hydrochloride tablets) prescribing information. Indianapolis, IN.

  63. Fisher B, Costantino JP, Wickerham DL, et al. 1998 Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371–1388.

    Article  PubMed  CAS  Google Scholar 

  64. Paganini-Hill A, Clark LJ. 2000 Eye problems in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat 60:167–172.

    Article  PubMed  CAS  Google Scholar 

  65. Delmas PD, Bjarnason NH, Mitlak BH, et al. 1997 Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. St. Louis College of Pharmacy and Community Clinical Pharmacist, Schnucks Pharmacy, 4588 Parkview Place, 63110-1088, St. Louis, MO

    Nicole M. Petersen PharmD

  2. Clinical Pharmacist and Pharmacy Consultant, Soldotna Professional Pharmacy, Soldotna, AK

    Amber L. Briggs PharmD

Authors
  1. Nicole M. Petersen PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Amber L. Briggs PharmD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole M. Petersen PharmD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Petersen, N.M., Briggs, A.L. Selective estrogen receptor modulators. Clinic Rev Bone Miner Metab 3, 19–30 (2005). https://doi.org/10.1385/BMM:3:1:019

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1385/BMM:3:1:019

Key Words

Search

Navigation